Cell Biotech Reports Operating Profit of 2.5 Billion KRW in H1, Up 27% YoY

Sales of 24.3 Billion KRW and Net Profit of 6.2 Billion KRW

Cell Biotech 4th Factory.

[Asia Economy Reporter Lee Gwan-ju] Cell Biotech announced on the 8th that its operating profit for the first half of this year increased by 27.0% compared to the same period last year, reaching 2.5 billion KRW. During the same period, sales amounted to 24.3 billion KRW, and net profit was 6.2 billion KRW, increasing by 10.0% and 73.3%, respectively.

A Cell Biotech official explained, "Exports to Asia and Europe have increased, and the domestic online business contributed to sales growth."

The "Korean-made probiotics" developed by Cell Biotech are exported to more than 40 countries worldwide, including Denmark, the pioneer country of probiotics, due to their excellent quality, and have ranked first in domestic probiotics exports for eight consecutive years.

Cell Biotech is a microbiome-specialized company that has researched "100% Korean-made premium probiotics" for 27 years. It holds patented technology for strains derived from the Korean human body and numerous clinical data targeting Koreans. It operates microbiome-specialized businesses such as the probiotics brand "Duolac," the microbiome skincare brand "Lacto Clear," and the customized gut health care service "Cell Biome."